On 26 July 2018, Omeros Corporation announced that the European Medicines Agency's (EMA's) Committee for Orphan Medicinal Products (COMP) have positively recommended the lead human monoclonal antibody named OMS721 for stem cell transplantation therapy.
The FDA held up Mersana’s top antibody-drug conjugate (ADC), XMT-1522 over safety issues following a patient’s death in phase 1 trial, causing a descent in the company’s shares.
The Newton Massachusetts-based company, Karyopharm Therapeutics, who developed a new class of drugs to treat multiple myeloma, is in the process of submitting a new drug application to the FDA for their selinexor drug.
Age-related Macular Degeneration (AMD) is the leading cause of blindness among the elderly. The most commonly used drugs to slow the progression of the disease is Roche’s Lucentis and Regeneron’s Eylea. These drugs are injected into the eye which, needless to say, leads to more inconvenience.
Stanford University School of Medicine Researchers have developed a magnetic wire that catches tumor cells flowing in the bloodstream. The wire, inserted into a vein, captures even limited tumor cells, ushering in a new means to detect cancer early.
The HCV RNA PCR test is a blood test that is advised by doctors in suspected patients to diagnose Hepatitis C infection. It calculates the hepatitis C viral load in the bloodstream. This article gives an insight into how the test functions and what the results signify.
Switzerland-based NBE Therapeutics AG, a biopharmaceutical company, announced a $20 million extension of series B funding led by Novo Holdings. Earlier in the series B funding round, the company had received $20 million, bringing the total funding to $40 million. The Swiss startup will use the new funding for the testing of the anti-ROR1 antibody-drug conjugate (ADC) NBE-002 in patients with solid tumors.
Last Friday, pharma giant AstraZeneca announced that it had received the go-ahead from the Drug Controller General of India (DCGI) to import and market durvalumab (ImfinziTM) in India. The receipt of this permission paves the way for the launch of durvalumab (ImfinziTM) in India. Durvalumab which is a patented drug of Astra-Zeneca, received permission in India to provide treatment for patients with unresectable non-small cell lung cancer and metastatic urothelial carcinoma.
San Francisco based Healthcare venture capital firm Alta Partners has launched funds titled as Alta Partner NextGen Fund I. The new fund will focus on the new development of therapeutics and health technology services. This will be the 9th fund in Alta Partners firms History.
This is the second partnership of the firm, the first outside oncology. It has a USD 790 million collaboration signed in 2016 with drugmaker Takeda of Japan. The deal with Zai Lab is the first for Crescendo to involve a specific pipeline asset. The deal with Takeda was more of a platform agreement giving it the required confidence to collaborate with other programs in oncology.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.